Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 41
Filtrar
3.
Antimicrob Agents Chemother ; 55(3): 1222-8, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21220537

RESUMO

Escherichia coli and the antimicrobial pressure exerted on this microorganism can be modulated by factors dependent on the host. In this paper, we describe the distribution of antimicrobial resistance to amikacin, tobramycin, ampicillin, amoxicillin clavulanate, cefuroxime, cefoxitin, cefotaxime, imipenem, ciprofloxacin, fosfomycin, nitrofurantoin, and trimetoprim-sulfametoxazole in more than 100,000 E. coli isolates according to culture site and patient age, gender, and location. Bayesian inference was planned in all statistical analysis, and Markov chain Monte Carlo simulation was employed to estimate the model parameters. Our findings show the existence of a marked difference in the susceptibility to several antimicrobial agents depending on from where E. coli was isolated, with higher levels of resistance in isolates from medical devices, the respiratory system, and the skin and soft tissues; a higher resistance percentage in men than in women; and the existence of a clear difference in antimicrobial resistance with an age influence that cannot be explained merely by means of an increase of resistance after exposure to antimicrobials. Both men and women show increases in resistance with age, but while women show constant levels of resistance or slight increases during childbearing age and greater increases in the premenopausal age, men show a marked increase in resistance in the pubertal age. In conclusion, an overwhelming amount of data reveals the great adaptation capacity of E. coli and its close interaction with the host. Sex, age, and the origin of infection are determining factors with the ability to modulate antimicrobial resistances.


Assuntos
Escherichia coli/efeitos dos fármacos , Escherichia coli/patogenicidade , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Amicacina/uso terapêutico , Ampicilina/uso terapêutico , Antibacterianos/uso terapêutico , Cefotaxima/uso terapêutico , Criança , Pré-Escolar , Ciprofloxacina/uso terapêutico , Farmacorresistência Bacteriana Múltipla , Infecções por Escherichia coli/tratamento farmacológico , Feminino , Fosfomicina/uso terapêutico , Humanos , Imipenem/uso terapêutico , Lactente , Masculino , Pessoa de Meia-Idade , Nitrofurantoína/uso terapêutico , Estudos Retrospectivos , Tobramicina/uso terapêutico , Adulto Jovem
4.
Pediatr Dermatol ; 28(1): 1-5, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-20553401

RESUMO

This report evaluates the June 2008 onychomadesis outbreak in Valencia, Spain. The study sample consisted of 221 onychomadesis cases and 77 nonaffected individuals who lived close to those affected. We collected data on dietary variables, hygiene products, and individual pathological histories. Feces and blood specimens were collected from 44 cases and 24 controls to evaluate exposure to infectious agents. Pathological background data revealed a high frequency (61%) of hand, foot, and mouth disease among the onychomadesis cases. Coxsackievirus A10 was the most commonly detected enterovirus in both case and control groups (49%). Other enteroviruses such as coxsackieviruses A5, A6, A16, B1, and B3; echoviruses 3, 4, and 9; and enterovirus 71 were present in low frequencies in the case and control groups (3-9%). The 2008 onychomadesis outbreak in the metropolitan area of Valencia was associated with an outbreak of hand, foot, and mouth disease primarily caused by coxsackievirus A10.


Assuntos
Surtos de Doenças , Enterovirus/classificação , Doença de Mão, Pé e Boca/complicações , Doença de Mão, Pé e Boca/epidemiologia , Doenças da Unha/epidemiologia , Doenças da Unha/virologia , Pré-Escolar , Enterovirus/isolamento & purificação , Fezes/virologia , Feminino , Doença de Mão, Pé e Boca/sangue , Humanos , Masculino , Doenças da Unha/sangue , Espanha/epidemiologia
5.
Antimicrob Agents Chemother ; 53(7): 3108-11, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19380590

RESUMO

We evaluated the in vitro activities of anidulafungin, micafungin, and caspofungin against Candida krusei by determining MIC and minimum fungicidal concentration (MFC) measurements and by the time-kill method. The geometric mean (GM)-MIC/GM-MFC values were 0.1/0.34, 0.25/0.44, and 1/2.29, respectively. The mean times to reach 99.9% growth reduction were 19.1 +/- 18.2 h (mean +/- standard deviation) for 2 mg/liter anidulafungin, 37.4 +/- 8.8 h for 2 mg/liter caspofungin, and 30.7 +/- 12.2 h for 1 mg/liter micafungin. Anidulafungin exhibited the highest time-kill rate, followed by micafungin. The three echinocandins showed fungicidal activity at concentrations reached in serum.


Assuntos
Antifúngicos/farmacologia , Candida/efeitos dos fármacos , Equinocandinas/farmacologia , Lipopeptídeos/farmacologia , Anidulafungina , Caspofungina , Micafungina , Testes de Sensibilidade Microbiana
6.
Rev Esp Geriatr Gerontol ; 54(6): 309-314, 2019.
Artigo em Espanhol | MEDLINE | ID: mdl-31307781

RESUMO

INTRODUCTION: The burden of disease due to pneumonia in older adults has a major impact on health systems. The aim of this study is to carry out an economic evaluation of the vaccination strategy against Streptococcus pneumoniae using the 13-valent pneumococcal conjugate vaccine. MATERIAL AND METHODS: A simulated economic model has been developed in the form of a decision tree to evaluate the cost of the vaccination strategy in the population over 65 years of the Valladolid-East Health Area, versus non-vaccination, using a Monte Carlo probabilistic analysis. RESULTS: Streptococcus pneumoniae annually generates 557.24 cases of pneumococcal disease in the Valladolid-East Health Area, and 506.60 episodes have pneumonia symptoms. Vaccination of the cohort over 65 years of age is an efficient measure from the third year, with a cost per quality-adjusted life years (QALY) of 20,496.20 €. The number of QALYs gained in a decade is 86.07 and an amount of 216.252.89 € with this vaccination strategy would be saved. CONCLUSIONS: The evaluation of the different incremental costs (QALY,euros) in the years of follow-up, the pneumococcus vaccination program in people over 65 in Castilla y León is cost-effective.


Assuntos
Vacinas Pneumocócicas/economia , Pneumonia Pneumocócica/prevenção & controle , Anos de Vida Ajustados por Qualidade de Vida , Streptococcus pneumoniae/imunologia , Vacinação/economia , Idoso , Infecções Comunitárias Adquiridas/economia , Infecções Comunitárias Adquiridas/epidemiologia , Infecções Comunitárias Adquiridas/prevenção & controle , Redução de Custos/economia , Árvores de Decisões , Hospitalização/estatística & dados numéricos , Humanos , Incidência , Modelos Econômicos , Vacinas Pneumocócicas/administração & dosagem , Pneumonia Pneumocócica/economia , Pneumonia Pneumocócica/epidemiologia , Espanha , Vacinas Conjugadas/administração & dosagem , Vacinas Conjugadas/economia
7.
Diagn Microbiol Infect Dis ; 62(2): 177-81, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18691842

RESUMO

The in vitro activity of posaconazole and voriconazole was evaluated by MIC, minimum fungicidal concentration (MFC), and time-kill methods. MFCs were determined for 15 Candida krusei and time-killing curves for 5 of these isolates. MFCs were obtained transferring 100 microL from clear MIC wells onto Sabouraud dextrose agar. Time-kill studies were performed in RPMI 1640 medium (5 mL, inoculum approximately 10(5) colony-forming unit [CFU]/mL). Geometric mean (GM) MIC and GM-MFC were 0.2 and 0.72 mg/L for posaconazole and 0.4 and 2.64 mg/L for voriconazole. The killing rate was isolate and concentration dependent; reductions in CFUs start at >or=0.12 mg/L (posaconazole) and >or= 0.5 mg/L (voriconazole). The mean time to reach a 90% growth reduction was 41.5+/-14.2 h (8 mg/L posaconazole) and 48.7+/-61.3 h (32 mg/L voriconazole). By time kill, a 99% killing rate was not reached by either agent. Both methods demonstrated that posaconazole (more active and greater killing rate) and voriconazole have fungicidal activity against C. krusei.


Assuntos
Antifúngicos/farmacologia , Candida/efeitos dos fármacos , Candida/crescimento & desenvolvimento , Pirimidinas/farmacologia , Triazóis/farmacologia , Candida/classificação , Candida/isolamento & purificação , Candidíase/microbiologia , Meios de Cultura , Farmacorresistência Fúngica , Fungemia/microbiologia , Humanos , Testes de Sensibilidade Microbiana , Fatores de Tempo , Voriconazol
8.
Diagn Microbiol Infect Dis ; 60(1): 109-12, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17889486

RESUMO

Candida guilliermondii fungemia is usually described in adults with hematologic malignancies, but in children, only 2 episodes have been published. From 1995 to 2006, 7 episodes (5 in children) were detected in our hospital. Molecular typing excluded a common infection source. C. guilliermondii fungemia may occur in children with underlying conditions other than cancer.


Assuntos
Candida/classificação , Candida/isolamento & purificação , Candidíase/microbiologia , Fungemia/microbiologia , Adulto , Criança , Pré-Escolar , Impressões Digitais de DNA , Feminino , Genótipo , Hospitalização , Humanos , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Epidemiologia Molecular , Técnicas de Tipagem Micológica , Técnica de Amplificação ao Acaso de DNA Polimórfico
9.
Rev Iberoam Micol ; 24(4): 312-6, 2007 Dec 31.
Artigo em Inglês | MEDLINE | ID: mdl-18095767

RESUMO

We report a case of disseminated histoplasmosis in a 33-year old Ecuadorian patient with AIDS and a CD4 lymphocyte count of 39 cells/microl. He presented with prolonged fever and cough, was diagnosed with hemophagocytic syndrome and multiple organ failure and died 18 days after admission. Histoplasma capsulatum was isolated post-mortem from bone marrow biopsy and blood culture. In a literature review we found 22 published cases of disseminated histoplasmosis in patients with AIDS in Spain since 1988. All but two were men under 50 years old. Nineteen had been born or had lived in endemic areas. The diagnosis of histoplasmosis was established by culture of bone marrow biopsy in 10 cases. Itraconazole was introduced as a second drug after amphotericin B in ten of the thirteen patients who survived.


Assuntos
Infecções Oportunistas Relacionadas com a AIDS/microbiologia , Histoplasmose/etiologia , Linfo-Histiocitose Hemofagocítica/etiologia , Adulto , Equador/etnologia , Evolução Fatal , Histoplasmose/diagnóstico , Histoplasmose/tratamento farmacológico , Histoplasmose/epidemiologia , Humanos , Masculino , Insuficiência de Múltiplos Órgãos/etiologia , Pancitopenia/etiologia , Espanha/epidemiologia , Viagem , Tuberculose Miliar/complicações
10.
Rev Iberoam Micol ; 24(2): 157-60, 2007 Jun.
Artigo em Espanhol | MEDLINE | ID: mdl-17604438

RESUMO

Native valve endocarditis caused by Aspergillus spp. is an uncommon disease with a high mortality rate. Generally, Aspergillus is isolated from affected valve in post-mortem or biopsy specimens. However, its isolation from blood cultures is exceedingly rare. We report a case of fungal endocarditis in a native mitral valve with the isolation of Aspergillus fumigatus both in valve vegetation and in blood culture bottles. The patient underwent valve replacement and antifungal treatment with voriconazole and caspofungin, but he died on post-operative day 45 with disseminated aspergillosis confirmed by necropsy. Paradoxically, galactomannan antigen detection in serum was negative. This is the third case of Aspergillus endocarditis with positive blood culture reported in the literature.


Assuntos
Antígenos de Fungos/sangue , Aspergilose/microbiologia , Aspergillus fumigatus/isolamento & purificação , Endocardite/microbiologia , Fungemia/microbiologia , Mananas/sangue , Valva Mitral/microbiologia , Amaurose Fugaz/etiologia , Aneurisma Infectado/etiologia , Aneurisma Infectado/microbiologia , Antifúngicos/uso terapêutico , Aspergilose/sangue , Aspergilose/complicações , Aspergilose/diagnóstico , Aspergilose/tratamento farmacológico , Aspergilose/cirurgia , Aspergillus fumigatus/imunologia , Biomarcadores , Caspofungina , Terapia Combinada , Equinocandinas , Endocardite/sangue , Endocardite/complicações , Endocardite/diagnóstico , Endocardite/cirurgia , Reações Falso-Negativas , Evolução Fatal , Fungemia/sangue , Fungemia/diagnóstico , Fungemia/tratamento farmacológico , Galactose/análogos & derivados , Implante de Prótese de Valva Cardíaca , Humanos , Infarto/etiologia , Infarto/microbiologia , Rim/irrigação sanguínea , Lipopeptídeos , Masculino , Artérias Mesentéricas/microbiologia , Oclusão Vascular Mesentérica/etiologia , Oclusão Vascular Mesentérica/microbiologia , Pessoa de Meia-Idade , Peptídeos Cíclicos/uso terapêutico , Doença Pulmonar Obstrutiva Crônica/complicações , Pirimidinas/uso terapêutico , Artéria Renal/microbiologia , Triazóis/uso terapêutico , Voriconazol
11.
Rev Med Inst Mex Seguro Soc ; 55(2): 170-175, 2017.
Artigo em Espanhol | MEDLINE | ID: mdl-28296367

RESUMO

BACKGROUND: The aim of this paper is to estimate the burden of hospitalization for community-acquired pneumonia and pneumococcal pneumonia at a tertiary level hospital in the Spanish National Health System. METHODS: A retrospective study which compiles data from the Minimum Data Set using clinical codes of the International Code of Diseases, as well as the hospitalization rate index per thousand inhabitants, the hospitalization rate per thousand population, mortality and fatality rate, using as denominator the demographic data of the population of the Health Area. RESULTS: The discharge of 5758 episodes coded with CIE codes 480 to 486 related to pneumonia, indicates an hospitalization rate of 3.54 people hospitalized per 1000 inhabitants, 65.34 % of all hospital admissions occured in Internal Medicine Services and Pneumology. The average hospital stay per year is 16.63 days. The crude death rate is 69.15 per 100 000 inhabitants and the fatality rate is 19.56 % being higher in adults over 65 years. CONCLUSIONS: Despite the current therapeutic and preventive measures, the incidence and mortality of community-acquired pneumonia in adults remains high, which justifies the strengthening and awareness to address new strategies and prevention such as vaccination.


Introducción: el objetivo de este trabajo es estimar la carga de hospitalización por neumonía adquirida en la comunidad y neumonía neumocócica en un hospital de nivel terciario del Sistema Nacional de Salud Español. Métodos: estudio retrospectivo en el que se recogen los datos del Conjunto Mínimo de Datos Básicos que usa códigos clínicos del Código Internacional de Enfermedades, asi como el índice de hospitalización por mil habitantes, la tasa de hospitalización por mil habitantes, el índice de mortalidad y la tasa de letalidad, usando como denominador los datos demográficos de la población del Área de Salud. Resultados: la descarga de 5758 episodios codificados con los códigos CIE 480 a 486 relativos a neumonía, señalan un índice de hospitalización de 3.54 personas hospitalizadas por cada 1000 habitantes, 65.34% del total de ingresos hospitalarios se produce en los Servicios de Medicina Interna y de Neumología. La estancia media hospitalaria por año es de 16.63 días. La tasa bruta de mortalidad es de 69.15 cada 100 000 y la tasa de letalidad de 19.56%, siendo más elevadas en adultos mayores de 65 años. Conclusiones: a pesar de las medidas terapéuticas y preventivas actuales, la incidencia y la mortalidad por neumonía adquirida en la comunidad en adultos se mantienen elevadas, lo que justifica fortalecer y abordar nuevas estrategias de concienciación y prevención.


Assuntos
Efeitos Psicossociais da Doença , Hospitalização/estatística & dados numéricos , Pneumonia Pneumocócica/epidemiologia , Centros de Atenção Terciária/estatística & dados numéricos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Infecções Comunitárias Adquiridas/epidemiologia , Infecções Comunitárias Adquiridas/terapia , Feminino , Humanos , Incidência , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Pneumonia Pneumocócica/terapia , Estudos Retrospectivos , Espanha/epidemiologia , Adulto Jovem
12.
Int J Food Microbiol ; 110(3): 286-90, 2006 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-16782223

RESUMO

We report four cases of blood cultures testing positive for yeast strains belonging to the species Saccharomyces cerevisiae. Using molecular techniques, RFLP of mtDNA and delta-PCR amplification, we show the association of two of the isolates with non-clinical strains. Specifically, with two commercial bread-making strains and the therapeutic S. boulardii strain. The association of S. boulardii with cases of fungemia has been reported previously. Nevertheless, this is the first time that a baker's yeast has been isolated from blood.


Assuntos
DNA Fúngico/análise , Microbiologia de Alimentos , Fungemia/microbiologia , Probióticos , Saccharomyces cerevisiae/isolamento & purificação , Idoso , Criança , DNA Mitocondrial/análise , Feminino , Humanos , Lactente , Masculino , Técnicas de Tipagem Micológica , Reação em Cadeia da Polimerase/métodos , Polimorfismo de Fragmento de Restrição , Saccharomyces cerevisiae/classificação , Saccharomyces cerevisiae/genética
16.
J Clin Virol ; 26(1): 79-84, 2003 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-12589837

RESUMO

Toscana virus (TOSV) is a member of the genus Phlebovirus that is transmitted to humans by two different species of sand fly and causes acute aseptic meningitis (AAM) and meningoencephalitis in Central Italy. Fifteen cases of AAM due to TOSV have been found at the Spanish province of Granada, but no data regarding the presence of TOSV-related disease in other regions of Spain have been still reported. A collection of 88 serum and 53 cerebrospinal fluid (CSF) samples taken from 81 selected patients with AAM of unknown aetiology, residing at Madrid or at the southern Mediterranean coast of Spain, was retrospectively studied for presence of TOSV-specific antibodies from both IgG and IgM classes. Anti-TOSV IgG was also investigated in 457 serum samples from healthy individuals, aged 2-60 years, residing at the south of the Region of Madrid. Specific IgM in serum and/or intrathecally produced anti-TOSV IgG were detected in seven patients, three residents from the Mediterranean region and the remainder four from the Region of Madrid. The overall prevalence of anti-TOSV among the healthy population studied was 5%. These results confirm the role of TOSV as an agent causing AAM in the Spanish Mediterranean coast, extend these findings to the central region of the country and suggest that TOSV might be producing infection and neurological disease in every area of Spain harbouring significant populations of the viral vectors.


Assuntos
Infecções por Bunyaviridae/epidemiologia , Meningite Viral/epidemiologia , Vírus da Febre do Flebótomo Napolitano/patogenicidade , Adolescente , Adulto , Idoso , Animais , Anticorpos Antivirais/sangue , Anticorpos Antivirais/líquido cefalorraquidiano , Infecções por Bunyaviridae/sangue , Infecções por Bunyaviridae/líquido cefalorraquidiano , Infecções por Bunyaviridae/virologia , Criança , Pré-Escolar , Feminino , Humanos , Imunoglobulina G/sangue , Imunoglobulina G/líquido cefalorraquidiano , Imunoglobulina M/sangue , Imunoglobulina M/líquido cefalorraquidiano , Lactente , Recém-Nascido , Insetos Vetores/virologia , Masculino , Região do Mediterrâneo/epidemiologia , Meningite Viral/sangue , Meningite Viral/líquido cefalorraquidiano , Meningite Viral/virologia , Pessoa de Meia-Idade , Psychodidae/virologia , Estudos Retrospectivos , Vírus da Febre do Flebótomo Napolitano/imunologia , Estações do Ano , Estudos Soroepidemiológicos , Espanha/epidemiologia , População Urbana , Viremia/epidemiologia , Viremia/virologia
17.
Diagn Microbiol Infect Dis ; 45(3): 203-6, 2003 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-12663162

RESUMO

Minimum fungicidal concentrations (MFCs) of amphotericin B were obtained for 165 bloodstream isolates (104 Candida parapsilosis, 14 C.glabrata, 13 C.tropicalis, 15 C.krusei, and 19 C.albicans) and 36 C.dubliniensis from oropharyngeal infections. Minimum inhibitory concentrations (MICs) were determined by the M27-A microdilution method. MFCs (> or =99.9% killing) were obtained following MIC determination (inoculum size, 10(4) CFU/ml) by seeding the entire volume of all clear wells. The best fungicidal activity was for C. albicans, (MFC90 1 microg/ml) and the lowest for C.parapsilosis, C.tropicalis and C.glabrata (MFC90 16 microg/ml). Although MFCs were > or =16x MIC for some isolates, including C. glabrata, the overall MFCs were > or =2x MICs. However, major differences between MICs and MFCs were observed for C.parapsilosis and C.dubliniensis (3.8% and 8.9%, respectively, were tolerant: MFC > or =32MIC). MFCs for C.tropicalis and C. glabrata were > or =2 microg/ml. By this more stringent method we found substantial differences from those previously reported between amphotericin B MIC and MFCs for Candida spp.


Assuntos
Anfotericina B/farmacologia , Antifúngicos/farmacologia , Candida/classificação , Candida/efeitos dos fármacos , Candidíase/sangue , Candidíase/microbiologia , Contagem de Colônia Microbiana , Feminino , Fungemia/sangue , Fungemia/microbiologia , Humanos , Masculino , Testes de Sensibilidade Microbiana , Sensibilidade e Especificidade
18.
Rev Iberoam Micol ; 21(2): 82-4, 2004 Jun.
Artigo em Espanhol | MEDLINE | ID: mdl-15538833

RESUMO

Candida glabrata is an emergent pathogen with diminished susceptibility to azoles, thus a rapid identification of this yeast could be of help to choose the appropriate treatment. GLABRATA RTT (Fumouze Diagnostics, France) is a new C. glabrata identification test. To evaluate its utility in the clinical laboratory daily routine, we prospectively tested 168 yeasts isolated in our hospital. GLABRATA RTT results had a sensitivity of 98.4% and a specificity of 100%. The combination of CHROMagar Candida isolation medium and GLABRATA RTT test allowed the identification of the four most common species in the clinical practice (Candida albicans, Candida tropicalis, Candida krusei and C. glabrata).


Assuntos
Candida glabrata/isolamento & purificação , Kit de Reagentes para Diagnóstico , Humanos , Sensibilidade e Especificidade , Fatores de Tempo
19.
Rev Iberoam Micol ; 20(3): 116-8, 2003 Sep.
Artigo em Espanhol | MEDLINE | ID: mdl-15456368

RESUMO

Serum galactomannan detection is considered to be a useful test for early diagnosis and follow-up of invasive aspergillosis. From February to September 2002, adult patients hospitalized in our Hematology Unit for receiving intensive chemotherapy and/or hematopoietic stem cell transplant were prospectively studied. We analyzed a total of 760 samples obtained from 100 patients. Eleven patients (11%) having a positive result (OD index >1.5 ng/ml) in two consecutive Platelia Aspergillus tests were considered galactomannan-positive cases. On the other hand, 12 patients (12%) were diagnosed of proven or probable invasive aspergillosis. Sensitivity (66.6%), specificity (95.5%), positive predictive value (72.7%) and negative predictive value (96.7%) were comparable to those of larger series. Galactomannan positivity allowed also to anticipate invasive aspergillosis diagnosis (from two to 17 days before radiographic findings and from two to 15 days before mycological culture). Moreover, kinetics of antigenemia could be useful for assessing therapeutic response. Once accepted galactomannan test as a diagnostic criterium for invasive aspergillosis knowing potential causes of false positive results is of paramount importance.


Assuntos
Antígenos de Fungos/sangue , Aspergilose Broncopulmonar Alérgica/diagnóstico , Ensaio de Imunoadsorção Enzimática , Fungemia/diagnóstico , Neoplasias Hematológicas/complicações , Mananas/sangue , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Aspergilose/sangue , Aspergilose/diagnóstico , Aspergilose/tratamento farmacológico , Aspergilose/microbiologia , Aspergilose Broncopulmonar Alérgica/sangue , Aspergilose Broncopulmonar Alérgica/tratamento farmacológico , Aspergilose Broncopulmonar Alérgica/etiologia , Aspergillus/imunologia , Aspergillus/isolamento & purificação , Biomarcadores , Terapia Combinada , Feminino , Seguimentos , Fungemia/tratamento farmacológico , Fungemia/etiologia , Galactose/análogos & derivados , Neoplasias Hematológicas/tratamento farmacológico , Neoplasias Hematológicas/terapia , Transplante de Células-Tronco Hematopoéticas , Humanos , Hospedeiro Imunocomprometido , Masculino , Pessoa de Meia-Idade , Neutropenia/induzido quimicamente , Neutropenia/complicações , Estudos Prospectivos , Sinusite/sangue , Sinusite/diagnóstico , Sinusite/tratamento farmacológico , Sinusite/microbiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA